The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.
Toni K. Choueiri
Consultant or Advisory Role - AVEO; Genentech; GlaxoSmithKline; Novartis; Novartis; Pfizer
Youjin Je
No relevant relationships to disclose
Guru Sonpavde
Consultant or Advisory Role - GlaxoSmithKline; Novartis
Honoraria - Novartis
Matt D. Galsky
No relevant relationships to disclose
Marina Kaymakcalan
No relevant relationships to disclose
Paul Linh Nguyen
No relevant relationships to disclose
Fabio Schutz
No relevant relationships to disclose
Daniel Yick Chin Heng
Consultant or Advisory Role - Novartis; Pfizer
Christopher J. Richards
No relevant relationships to disclose